Literature DB >> 27568579

Extracellular Adenosine 5'-Triphosphate in Obstructive Airway Diseases.

Amir Pelleg1, Edward S Schulman2, Peter J Barnes3.   

Abstract

In recent years, numerous studies have generated data supporting the hypothesis that extracellular adenosine 5'-triphosphate (ATP) plays a major role in obstructive airway diseases. Studies in animal models and human subjects have shown that increased amounts of extracellular ATP are found in the lungs of patients with COPD and asthma and that ATP has effects on multiple cell types in the lungs, resulting in increased inflammation, induction of bronchoconstriction, and cough. These effects of ATP are mediated by cell surface P2 purinergic receptors and involve other endogenous inflammatory agents. Recent clinical trials reported promising treatment with P2X3R antagonists for the alleviation of chronic cough. The purpose of this review was to describe these studies and outline some of the remaining questions, as well as the potential clinical implications, associated with the pharmacologic manipulation of ATP signaling in the lungs.
Copyright © 2016 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ATP; COPD; P2 receptors; cough; inflammation

Mesh:

Substances:

Year:  2016        PMID: 27568579     DOI: 10.1016/j.chest.2016.06.045

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  15 in total

Review 1.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

2.  The elevated CXCL5 levels in circulation are associated with lung function decline in COPD patients and cigarette smoking-induced mouse model of COPD.

Authors:  Jun Chen; Luqi Dai; Tao Wang; Junyun He; Yashu Wang; Fuqiang Wen
Journal:  Ann Med       Date:  2019-07-16       Impact factor: 4.709

Review 3.  Mitochondrial Dysfunction in Airway Disease.

Authors:  Y S Prakash; Christina M Pabelick; Gary C Sieck
Journal:  Chest       Date:  2017-03-21       Impact factor: 9.410

Review 4.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

Review 5.  Mitochondria signaling pathways in allergic asthma.

Authors:  Ling Qian; Entezar Mehrabi Nasab; Seyyede Masoume Athari; Seyyed Shamsadin Athari
Journal:  J Investig Med       Date:  2022-02-15       Impact factor: 3.235

Review 6.  Purinergic Signaling in Mast Cell Degranulation and Asthma.

Authors:  Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Front Pharmacol       Date:  2017-12-22       Impact factor: 5.810

7.  Is the purinergic pathway involved in the pathology of COPD? Decreased lung CD39 expression at initial stages of COPD.

Authors:  Elisabet Aliagas; Mariana Muñoz-Esquerre; Ester Cuevas; Oriol Careta; Daniel Huertas; Marta López-Sánchez; Ignacio Escobar; Jordi Dorca; Salud Santos
Journal:  Respir Res       Date:  2018-05-28

Review 8.  Adenosine 5'-triphosphate's role in bradycardia and syncope associated with pulmonary embolism.

Authors:  Amir Pelleg; Edward S Schulman; Peter J Barnes
Journal:  Respir Res       Date:  2018-07-28

9.  Tiotropium and Fluticasone Inhibit Rhinovirus-Induced Mucin Production via Multiple Mechanisms in Differentiated Airway Epithelial Cells.

Authors:  Ying Wang; Dennis K Ninaber; Annemarie van Schadewijk; Pieter S Hiemstra
Journal:  Front Cell Infect Microbiol       Date:  2020-06-19       Impact factor: 5.293

Review 10.  The role of ATP in cough hypersensitivity syndrome: new targets for treatment.

Authors:  Mengru Zhang; Shengyuan Wang; Li Yu; Xianghuai Xu; Zhongmin Qiu
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 3.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.